AbbVie Inc.

ABBV

US00287Y1091

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Employees

50,000

Sector

Pharmaceuticals

Calendar

2025-01-14 - Détachement de

More about the company

Income Statement and Estimates

income-statement-evolution-chart ABBVIE-INC

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

175.67USD

Average target price

202.67USD

Spread / Average Target

+15.37%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 04:00:02 2024-12-10 pm EST			5-day change	1st Jan Change
175.67 ^USD	-0.51%		-3.36%	+13.36%

Dec. 09	AbbVie Reports Durable Results from Mono, Combo Therapy for Blood Cancer	MT
Dec. 09	Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma	CI

AbbVie Reports Durable Results from Mono, Combo Therapy for Blood Cancer	Dec. 09	MT
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma	Dec. 09	CI
AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study -- Update	Dec. 09	DJ
Correction to AbbVie Tavapadon Phase 3 Study Article	Dec. 09	DJ
AbbVie's Phase 3 Trial of Tavapadon for Parkinson's Disease Meets Endpoints	Dec. 09	MT
AbbVie's Tavapadon Hits Key Goals in Second Phase 3 Parkinson's Study	Dec. 09	DJ
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease	Dec. 09	CI
AbbVie Inc. Announces Updated Results from the Phase 1b/2 EPCORE® NHL-2 Trial Evaluating Fixed-Duration Investigational Epcoritamab	Dec. 07	CI
Wall Street's gravity-defying rally awaits non-farm payrolls verdict	Dec. 05
Analyst recommendations: Applovin, Chewy, Netflix, Deliveroo, Diageo...	Dec. 05
Daiwa Securities Downgrades AbbVie to Neutral From Outperform, Adjusts Price Target to $180 From $210	Dec. 05	MT
Indices: oil, health, industry... very typical of Nordic indices	Dec. 03
AbbVie Inc. Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 10:15 AM	Dec. 03
AbbVie Shares Rise as Leerink Partners Upgrades Stock	Nov. 22	MT
Wall Street warms to AI's glow	Nov. 22
Leerink Partners Upgrades AbbVie to Outperform From Market Perform, Price Target is $206	Nov. 22	MT
Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application	Nov. 18	DJ
Wells Fargo Adjusts Price Target on AbbVie to $195 From $205, Maintains Overweight Rating	Nov. 18	MT
Aldeyra Therapeutics' Resubmitted Marketing Application for Eye Disease Drug Accepted by FDA	Nov. 18	MT
AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer	Nov. 18	DJ
Roche: CE marking in ovarian cancer	Nov. 18	CF
AbbVie Says Elahere Gets Approval From European Commission as Ovarian Cancer Treatment	Nov. 18	MT
Abbvie Receives European Commission Approval of Elahere (Mirvetuximab Soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer	Nov. 18	CI
Redburn Atlantic Adjusts AbbVie's Price Target to $216 From $215, Keeps Buy Rating	Nov. 15	MT
Deutsche Bank Adjusts Price Target on AbbVie to $177 From $180, Keeps Hold Rating	Nov. 14	MT

AbbVie Inc.

Equities